Načítá se...
Interstitial lung disease induced by docetaxel and ramucirumab chemotherapy after nivolumab treatment
Three men (aged 64, 65, and 67 years) with advanced lung cancer who had been treated with nivolumab developed interstitial lung disease (ILD) during chemotherapy with docetaxel and ramucirumab. The treatment was clinically effective; however, the patients experienced immune‐related adverse effects d...
Uloženo v:
| Vydáno v: | Respirol Case Rep |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley & Sons, Ltd
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7176744/ https://ncbi.nlm.nih.gov/pubmed/32337046 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rcr2.564 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|